CARsgen climbs 6% as CAR-T therapy enters commercial insurance catalogMarket Movers·Nov 16, 2026 at 01:31 AM02171-3.35%
CARsgen's CAR-T Product Satri-cel Included in China's Commercial Health Insurance Innovative Drug Listprnewswire·Nov 14, 2026 at 09:56 AM02171-3.35%
Brii Biosciences Files HKEX Next-Day Disclosure Return Announcing Share BuybackPUBT·Nov 6, 2026 at 01:17 PM02171-3.35%
CARsgen publishes CT1190B lymphoma study abstract for ASH 2026PUBT·Nov 5, 2026 at 12:01 AM02171-3.35%
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026MorningStar·Oct 26, 2026 at 12:43 AM02171-3.35%
Weekly Recap | CARSGEN-B -3.86%, outperforming Hang Seng IndexWeekly Review·Oct 24, 2026 at 05:17 AM02171-3.35%
Renaming is the easy part. Hong Kong's small caps are learning the hard partGlobal Report·Oct 21, 2026 at 10:51 AM00117+2.34%01937-0.71%
USD 1.16B Rights Issue, a 52% Plunge: Hong Kong Small Caps Rewrite PlaybooksGlobal Report·Oct 13, 2026 at 10:52 AM019390.00%01208-2.67%
Niche Hong Kong Small-Caps Bet Big on Copper, AI Components and IP CollaborationsGlobal Report·Oct 13, 2026 at 09:25 AM00117+2.34%00517-0.36%
CARsgen starts registrational trial for allogeneic CAR T therapy CT0596 in ChinaTip Ranks·Oct 13, 2026 at 12:07 AM02171-3.35%